Lineage Cell Therapeutics

Rapid Advances Will Redefine Regenerative Medicine For Aging Populations

AnalystHighTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

12 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

US$8.85

86.4% undervalued

16 Aug

US$1.20

36.3%

18.8%

Author's Valuation

US$8.8

86.4% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$8.8

86.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

46.29%

Biotech revenue growth rate

13.11%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$10.58m

Earnings '28

411.13x

PE Ratio '28

US$4.35b

Market Cap '28

US$4.35b

Market Cap '28

403.82m

No. shares '28

US$10.77

Share Price '28

US$10.77 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$8.85

Fair Value '25